Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Elekta AB (publ)
  6. News
  7. Summary
    EKTA B   SE0000163628

ELEKTA AB (PUBL)

(EKTA B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Elekta : Unity MR-Linac featured in 72 abstracts at European radiation oncology congress

08/31/2021 | 01:31am EDT

MADRID, August 31, 2021 - Elekta (EKTA-B.ST) today announced the presentation of 72 abstracts demonstrating the technical capabilities and clinical utility of the Elekta Unity MR-Linac. The research described in the abstracts was conducted at 14 leading cancer centers worldwide, reflecting the broad global adoption of the system. The abstracts were reported at the European SocieTy for Radiotherapy and Oncology (ESTRO) which took place 27-31 August in Madrid, Spain.

"The Elekta Unity data presented at ESTRO include a growing number of abstracts reporting clinical data in multiple anatomic sites, which is a direct result of the increased clinical implementation and maturation," said Kevin Brown, Distinguished Scientist at Elekta. "We are especially excited about eight reports regarding MRI-based biomarkers that may predict response to therapy, which may help optimize patient selection and ensure that patients receive personalized treatment based on their unique tumor biology. These reports demonstrate the ease with which this biomarker data can be acquired during a Unity treatment session which lowers a barrier to impactful research. This ease will also be essential for eventual cost-effective implementation of the research findings. There are also several abstracts that utilize data from the MOMENTUM study, which is designed to build a robust body of real-world clinical data and insights and facilitate understanding of how Elekta Unity may be deployed in clinical practice to improve patient outcomes."

Mr. Brown highlighted several abstracts that exemplify the innovative approaches that members of the MR-Linac Consortium are pursuing to optimize the clinical use of Elekta Unity in real-world settings:

Radiographer-led online image guided adaptive radiotherapy: A qualitative investigation
To maintain and increase uptake of MRgRT's cutting-edge technology, traditional roles and responsibilities for radiographers, clinicians and physicists may need to evolve. This abstract describes an effort to provide an in-depth understanding and subsequent impact of the roles required to deliver MRgRT using Focus Group Interviews. Thirty participants took part (Radiographers: n=18, Physicists: n=9 and Clinicians: n=3), and the consensus among the group was to move toward a radiographer-led process with training preferably delivered in a blended way, both before and during treatments. The authors conclude that roles must be created with sufficient support and robust governance to enable evaluation of effectiveness, impact, ongoing sustainability, and responsiveness. A training framework created collaboratively with all stakeholders and professions involved would ensure consistency in skills and knowledge.

First results from the national network for quality assurance of MR images in RT in Denmark
MRI images are less geometrically accurate compared with CT images, which can impact radiation dose delivery in MRgRT. This abstract describes the first results from a Danish national network for quality assurance (QA) of MR images used in radiation therapy in Denmark. A general MRI sequence was used to test the geometric accuracy of MRI scanners (n=8) and MR-linacs (n=2) at seven of eight Danish radiation therapy centers and one radiology department. Except for one MRI scanner, the results were below 0.43 mm within 200 mm diameter spherical volume and below 1.2 mm for a 350 mm diameter spherical volume (DSV). No dependence on magnetic field strength was seen. These findings demonstrate both the ability to deliver an MR-led precision radiation therapy workflow and the value of QA systems in optimizing MRgRT.

MR-guided SBRT for localized prostate cancer: the first results from the MOMENTUM study
As the first high-field MR-guided radiation therapy system, Elekta Unity enables new treatment approaches for a broad array of cancers, including prostate cancer. To ensure that the promise of this technology is fully realized, the MR-linac Consortium launched the MOMENTUM study, which is designed to build a robust body of real-world clinical data and insights regarding implementation and use of Elekta Unity. This abstract describes the first data output from the MOMENTUM study, and includes short-term results (three and six months of follow-up [FU]) for 156 patients with prostate cancer treated with ultrahypofractionated radiation therapy (5 x 7.25 Gray). No grade ≥3 genitourinary or gastrointestinal toxicity was reported, and no significant deterioration of patient-reported outcomes scores were observed. The percentage of men reporting no difficulty getting or maintaining an erection remained constant throughout FU (44.4% at baseline, 40.0% at 3 months FU, and 42.9% at 6 months FU). These findings support the safety and efficacy of ultrahypofractionated radiation therapy delivered with Elekta Unity for the treatment of prostate cancer.

Repeatability of diffusion-weighted MRI in head and neck cancer at a 1.5 T MR-Linac
For imaging biomarkers acquired on MR-Linacs to be useful they need to be accurate, repeatable on individual patients, and reproducible across different MR-Linacs. The aim of this study was to determine the repeatability of apparent diffusion coefficient values derived from diffusion-weighted MRI in patients with head and neck cancer acquired on Elekta Unity. When analyzed at the Volume of Interest level the within subject coefficient of Variation ranged between 3.3% in the parotid glands and 8.3% in the GTV. These are promising results and support further development towards quantitative MRI for online adaptive RT.

To learn more about Elekta Unity, visit elekta.com/Unity.

Elekta Unity has CE mark and 510(k) clearance but is not available in all markets.

# # #

For further information, please contact:
Mattias Thorsson, Vice President, Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com  
Time zone: CET: Central European Time

Raven Canzeri, Global Public Relations Manager
Tel: +1 770 670 2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,400 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

https://news.cision.com/elekta/r/elekta-unity-mr-linac-featured-in-72-abstracts-at-european-radiation-oncology-congress,c3406468

https://mb.cision.com/Main/35/3406468/1461674.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about ELEKTA AB (PUBL)
09/02ELEKTA : acquires Turkish distributor to strengthen market position
AQ
09/02ELEKTA AB (OM : EKTA B) acquired Özyürek Mümessillik ve Dis Ticaret A.S.
CI
08/31ELEKTA : Unity MR-Linac featured in 72 abstracts at European radiation oncology congress
AQ
08/31Elekta Unity MR-Linac Featured in 72 Abstracts At European Radiation Oncology Congress
CI
08/26ELEKTA : Board announces establishment of philanthropic Elekta Foundation
AQ
08/26ELEKTA AB (PUBL) : Ex-dividend day for interim dividend
FA
08/25GLOBAL MARKETS LIVE : Kering, Delta Air Lines, Pfizer, Moderna, Sony...
08/25ELEKTA : Report from the Annual General Meeting 2021 in Elekta
AQ
08/25Elekta AB Approves Dividend, Payable on 1 September 2021 and on 3 March 2022
CI
08/25Elekta AB Resolves on Dividend into Two Payments, Payable on 1 September 2021 and on 3 ..
CI
More news
Financials
Sales 2022 14 928 M 1 742 M 1 742 M
Net income 2022 1 363 M 159 M 159 M
Net Debt 2022 889 M 104 M 104 M
P/E ratio 2022 27,9x
Yield 2022 2,08%
Capitalization 38 025 M 4 432 M 4 438 M
EV / Sales 2022 2,61x
EV / Sales 2023 2,40x
Nbr of Employees 4 000
Free-Float 93,8%
Chart ELEKTA AB (PUBL)
Duration : Period :
Elekta AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELEKTA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 99,52 SEK
Average target price 118,09 SEK
Spread / Average Target 18,7%
EPS Revisions
Managers and Directors
Gustaf Salford President & Chief Executive Officer
John Adebäck Chief Financial Officer & Group Treasurer
Laurent Leksell Chairman
Steven Mark Wort Chief Operating Officer
Caroline Mofors Chief Compliance & Integrity Office, Senior VP
Sector and Competitors
1st jan.Capi. (M$)
ELEKTA AB (PUBL)-9.90%4 432
THERMO FISHER SCIENTIFIC30.62%240 757
DANAHER CORPORATION39.88%223 934
INTUITIVE SURGICAL, INC.25.24%122 004
SIEMENS HEALTHINEERS AG40.64%77 031
EDWARDS LIFESCIENCES CORPORATION26.87%72 674